메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates…

BEIJING, Nov. 27, 2025 -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adults with obesity or overweight. In this study, bofanglutide injection will be administered subcutaneously once every four weeks (once-monthly) to explore its potential to maintain the achieved weight loss and improved long-term adherence. This phase 3 study (Chinadrugtrials.org.c
- 김갑성 기자
- 2025-11-27 16:57
IASO Bio Announces BLA Approval of Fucaso (Equecabtage…

SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, today announced that the Biologics License Application (BLA) for its independently developed fully human anti-BCMA CAR-T therapy Fucaso (Equecabtagene Autoleucel) has been approved by the Hong Kong Department of Health. The therapy is indicated for adult patients with rel
- 김갑성 기자
- 2025-11-27 13:44
GC Genome Publishes Blood-Based Colorectal Cancer Scre…

YONGIN, South Korea, Nov. 27, 2025 -- GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik's team at Asan Medical Center has been published in The American Journal of Gastroenterology(AJG). GC Genome applied its proprietary AI-based fragmentomics technology, used in its MCED test, ai-CANCERCH. This study demonstrates the potential for a convenient, alternative to colonoscopy and fecal based screening methods, while enabling early detection of colorectal cancer and advanced adenomas
- 김갑성 기자
- 2025-11-27 13:00
SK Biopharmaceuticals Expands Radiopharmaceutical Th…

[ 메디채널 김갑성 기자 ] New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 27, 2025 -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology, announced a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire the exclusive worldwide rights for research and development (R&D), manufa
- 김갑성 기자
- 2025-11-27 10:39
Patronus Biotech receives grant to evaluate a novel malaria…

SINGAPORE, Nov. 27, 2025 -- Patronus Biotech today announced a grant from the Gates Foundation to accelerate the development of its novel malaria vaccine and adjuvant program to support affordable access and use in global health. The funding will enable the evaluation of an innovative U-VLP® vaccine candidate, LYB014, which targets multiple stages of the most deadly form of malaria parasite's life cycle; as well as a new, low cost, highly pure adjuvant manufactured from synthetic components. Malaria remains one of the world's most devastating infectious diseases, with an es
- 김갑성 기자
- 2025-11-27 09:00
Healgen Scientific Spotlights the Rapid Check® COVID-19/Flu A&…

HOUSTON, Nov. 27, 2025 -- As the holiday season approaches, gatherings among family and friends are expected to increase the risk of respiratory virus transmission, including COVID-19 and influenza. In response, Healgen® Scientific highlights the Rapid Check® COVID-19/Flu A&B Antigen Test, a 3-in-1 at-home rapid test designed to help users quickly distinguish between COVID-19 and common flu viruses. According to the U.S. Centers for Disease Control and Prevention (CDC), the upcoming 2025–2026 respiratory disease season is expected to bring a comparable level of hosp
- 김갑성 기자
- 2025-11-27 00:00
TCI Biotech Inaugurates Advanced Performance Nutrition Re…

SALT LAKE CITY, Nov. 27, 2025 -- TCI Biotech (TCI Co., Ltd.), a global CDMO+ specializing in functional foods, nutraceuticals, and beauty supplementation, today announced the launch of the TCI Advanced Performance Nutrition Research Center, a new innovation hub focused on high-performance nutrition, cognitive wellness, healthy aging, and sports performance. This milestone marks TCI's strategic entry into the fast-growing field of brain science, supported by new research programs in regenerative medicine, cellular biology, and neuro-supportive ingredient technologies. The opening of the
- 김갑성 기자
- 2025-11-27 00:00
China Cycle 2026: Building An Innovation Driven, Intelligence-…

SHANGHAI, Nov. 26, 2025 -- The 34th China International Bicycle Fair (China Cycle 2026) is expected to unveil the grand exhibition from May 5 to 8, 2026 at the Shanghai New International Expo Center (SNIEC), themed "Innovation-Driven, Intelligence-Led Future." Building on three decades of expertise and innovation, China Cycle has become a pivotal hub shaping global trends in the bicycle and e-bike industries and a leading professional platform with deep industry influence. In 2024, China's total bicycle production reached nearly 99.54 million, the imports of race bicy
- 김갑성 기자
- 2025-11-26 22:10
2026년 상하이 국제 자전거 박람회: 혁신을 원동력 삼은 첨단 기술 중심의 미래 건설

[ 메디채널 김갑성 기자 ] 상하이 2025년 11월 26일 -- 차이나 사이클(China Cycle)로도 알려진 제34회 상하이 국제 자전거 박람회(China International Bicycle Fair)가 '혁신을 원동력 삼은 첨단 기술 중심의 미래(Innovation-Driven, Intelligence-Led Future)'를 주제로 2026년 5월 5일부터 8일까지 상하이 신국제 엑스포센터(Shanghai New International Expo Center, SNIEC)에서 열릴 예정이다. 이나 사이클은 30년간 전문성과 혁신을 축적하면서 세계 자전거 및 전기 자전거 산업의 유행을 이끄는 구심점이자 업계에 막대한 영향을 미치는 세계 유수의 행사로 자리매김했다. 2024년 중국의 총 자전거 생산량은 약 9954만 대에 달했다. 경기용 자전거 수입량은 전년 대비 12.5% 증가했으며, 고급 전기 자전거가 지난해 전체 시장에서 차지하는 비중은 19.1%였다. 전략적 교두보 역할을 하는 상하이 국제 자전거 박람회는 해외 기업들이 중국의 광범위한 시장의 문을 직접 두드린 후 중국 소비자 심리에 대한 의미심장한
- 김갑성 기자
- 2025-11-26 22:10
Celltrion announces publication of post-hoc analysis of L…

Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) Findings support the therapeutic potential of ZYMFENTRA in addressing persistent treatment gaps especially in ileum-dominant CD INCHEON, South Korea, Nov. 26, 2025 -- Celltrion, Inc. today announced that a post-hoc analysis of the LIBERTY-CD study, which showed that the efficacy of ZYMFENTRA® (infliximab-dyyb) is consistent regardless of disease l
- 김갑성 기자
- 2025-11-26 14:48

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 20시 10분